When GLP-1 Side Effects Mean You Should Call Your Prescriber

Most of what you'll experience on a GLP-1 medication — mild nausea, some fatigue, occasional constipation — is expected and manageable. But a small number of symptoms are different: they're genuine warning signs that call for medical attention rather than home management. Knowing the difference matters, and it isn't always obvious in the moment.

Severe, persistent abdominal pain — possible pancreatitis

This is the most important warning sign to know. Acute pancreatitis is a rare but documented risk associated with GLP-1 medications, and the UK's medicines regulator, the MHRA, has specifically flagged the importance of patients and clinicians being alert to its warning signs given how widely these medications are now used (Pharmaphorum, 2026). Roughly 1.6 million UK adults have used a GLP-1 medication in the past year, which is exactly why regulatory bodies are emphasising awareness now (Pharmaphorum, 2026).

The classic pattern is severe, persistent upper abdominal pain that may radiate to the back, often accompanied by nausea and vomiting (Pharmaphorum, 2026; StemVera Health, 2026). This is meaningfully different from typical GLP-1-related nausea — it's more intense, doesn't ease with the usual measures, and the pain pattern itself (persistent, radiating to the back) is the key distinguishing feature (StemVera Health, 2026).

If pancreatitis is suspected, product safety guidance consistently advises stopping the medication and seeking medical attention immediately, rather than treating it as a routine side effect to push through (StemVera Health, 2026; Noom, 2025). Risk factors that increase susceptibility include a previous history of pancreatitis, gallbladder disease, very high triglyceride levels, and heavy alcohol use — worth flagging to your prescriber before starting treatment if any apply to you (Noom, 2025). It's worth noting that the FDA's own development data for semaglutide did not show an increased risk of pancreatitis compared to placebo, and regulators are clear that this remains a rare event given how many people use these medications safely (Noom, 2025) — the point isn't that it's common, but that it needs to be recognised quickly if it does occur.

Signs of gallbladder problems

Gallbladder issues, including gallstones, are a recognised side effect of GLP-1 medications, and it isn't yet fully clear whether the medications themselves cause gallstones or whether they result from the rapid weight loss the medications produce (Pharmaphorum, 2026). Warning signs to watch for include pain in the upper stomach, yellowing of the skin or eyes (jaundice), fever, and clay-coloured stools (GRABS Trial protocol, ClinicalTrials.gov, 2024).

Signs of a serious allergic reaction

Though rare — occurring in fewer than 1% of patients — serious allergic reactions are a recognised risk with GLP-1 medications. Warning signs include swelling of the face, lips, tongue, or throat, a severe rash or itching, a very rapid heartbeat, difficulty breathing or swallowing, or fainting and dizziness (GRABS Trial protocol, ClinicalTrials.gov, 2024). These symptoms require emergency medical attention, not a wait-and-see approach.

Severe or persistent vomiting, and signs of dehydration

Clinical trial safety guidance specifically advises patients to notify their prescriber in case of severe nausea, frequent vomiting, or symptoms of dehydration, since these can lead to a deterioration in kidney function, including acute kidney injury in rare cases (Long-term Safety Study, ClinicalTrials.gov, 2024; NCT05786521 trial data). This is a meaningfully different threshold from the mild, manageable nausea that's common and expected in the first weeks of treatment.

The thyroid cancer boxed warning

Tirzepatide carries a black box warning — the FDA's most serious labelling requirement — for a theoretical risk of medullary thyroid carcinoma, a rare form of thyroid cancer (GRABS Trial protocol, ClinicalTrials.gov, 2024). This warning stems from animal studies showing a higher rate of these tumours; whether the same risk applies to humans remains unknown (GRABS Trial protocol, ClinicalTrials.gov, 2024). Anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not be prescribed these medications, and any new lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath during treatment warrants prompt medical evaluation.

Symptoms that don't need urgent attention, but do need mentioning

Not everything requires an emergency call — but it's still worth flagging to your prescriber at your next check-in: constipation or diarrhoea that isn't improving after a few weeks of dietary changes, ongoing significant fatigue, or worsening of pre-existing diabetic eye disease (retinopathy), which has been specifically identified as a less common but recognised risk with semaglutide (NCT05786521 trial data, 2024).

A general principle worth remembering

Across nearly every warning sign above, one pattern repeats: severity and persistence are what separate a normal side effect from a genuine warning sign. Mild nausea that improves with smaller meals is normal. Severe, unrelenting pain that doesn't respond to anything is not. When in doubt, contacting your prescriber costs you nothing — waiting on a genuine warning sign can cost considerably more.

Where structured support fits into staying safe

Knowing what's normal versus what isn't is exactly the kind of judgement that's hard to build on your own from scattered forum posts and conflicting articles. Having consistent, structured support alongside your medication means having someone to check in with regularly, rather than only reaching out once something feels seriously wrong.

This is part of what our While You're On It programme is built to provide — ongoing support through your treatment that complements, rather than replaces, your prescriber relationship.

If you're managing digestive side effects and want nutritional support that keeps you well-nourished throughout treatment, our Alongside Daily Support powder can help fill gaps when appetite or tolerance is reduced.

When it's time to plan your transition off treatment, our Coming Off It programme supports that phase specifically.

And if you want a second, structured perspective on symptoms you're noticing — always alongside, never instead of, your prescriber's medical judgement — our 1:1 coaching is available to help you navigate it.

The bottom line

Most GLP-1 side effects are mild, expected, and manageable at home. A specific, smaller set of symptoms — severe abdominal pain radiating to the back, jaundice or fever suggesting gallbladder trouble, signs of a serious allergic reaction, severe vomiting with dehydration, or a new lump or hoarseness in the neck — are genuine warning signs that need prompt medical attention. Knowing this list in advance, before you're in the moment of deciding whether something is "just a side effect," is one of the most useful things you can do when starting treatment.

This article is for general information and isn't a substitute for medical advice. If you experience any of the warning signs described here, contact your prescriber or seek emergency medical attention immediately.

References

ClinicalTrials.gov. (2024). Effect of GLP1 receptor agonists on physical function, body composition, and markers of aging in older adults (NCT05786521) [Informed consent form]. https://cdn.clinicaltrials.gov/large-docs/21/NCT05786521/ICF_000.pdf

ClinicalTrials.gov. (2024). GLP-1 receptor agonists post-bariatric surgery (GRABS) pilot trial (NCT06162715) [Informed consent form]. https://cdn.clinicaltrials.gov/large-docs/15/NCT06162715/ICF_000.pdf

ClinicalTrials.gov. (2024). A long-term safety study of tirzepatide (LY3298176) in participants with type 2 diabetes (NCT03861039) [Protocol]. https://cdn.clinicaltrials.gov/large-docs/39/NCT03861039/Prot_000.pdf

Noom. (2025, August 21). Ozempic and Wegovy pancreatitis symptoms: Risks & warning signs. https://www.noom.com/blog/weight-management/ozempic-pancreatitis-symptoms/

Pharmaphorum. (2026, January 30). GLP-1 drugs linked to pancreatitis, gallbladder problems. https://pharmaphorum.com/news/glp-1-drugs-linked-pancreatitis-gallbladder-problems

StemVera Health. (2026, February 15). GLP-1 pancreatitis warning signs: Symptoms & actions. https://www.stemvera.com/glp1-pancreatitis-warning-signs